Most material SEC filings — August 26, 2026

On June 10, 2026, Air T (through subsidiary Crestone Air Partners LLC) completed acquisition of Arena Aviation Partners B.V., a Netherlands aviation asset management company, for $21.7M cash plus $12.2M contingent consideration (57.5% of specified upside from servicing agreements), totaling $33.9M. The transaction was funded by $21.7M cash contribution from Air T and Blue Owl Capital, plus servicing agreement rights. Pro forma combined revenue for FY2026 would be $338.5M (Air T $327.1M + Arena $11.4M); pro forma net income to Air T shareholders $72.6M on that basis.

Arcline Investment Management completed its acquisition of AstroNova on August 26, 2026, purchasing all outstanding common stock at $29.00 per share in an all-cash transaction. AstroNova ceases trading on Nasdaq and becomes a private company. The filing also includes restated articles of incorporation and amended/restated bylaws effective upon completion.

On 2026-08-25, Avalanche Treasury Corp filed an 8-K disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No specific counterparties, dollar amounts, percentages, share counts, or detailed reasons for the delisting notice are disclosed in the filing header or document metadata provided. The filing indicates a material adverse listing event but lacks concrete operational or financial specifics.

On August 20, 2026, American Resources Corp received notice of failure to satisfy continued listing standards. The 8-K filing on August 26, 2026 reports Item 3.01 (delisting notice) and Item 9.01 (exhibits only). No specific cure period, remediation plan, or financial details are disclosed in the available filing text.

CaliberCos Inc. filed an 8-K on 2026-08-21 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing provides no specific details on which exchange rule was violated, remediation timeline, or specific listing standard deficiency. The actual 8-K document content is not provided in this submission extract.

Victory Capital agreed to acquire 100% of First Eagle Investments (approximately $222B AUM as of July 31, 2026) from Genstar Capital and First Eagle employees for total consideration of ~$7.0B ($4.4B cash, $2.0B equity, and assumption of $575M debt). Combined entity will have ~$571B in total client assets. Transaction is expected to close by end of Q1 2027 and deliver ~35% adjusted EPS accretion in 2027E, with ~$280M in anticipated net expense synergies and ~$3.2B in combined annual revenue. Genstar will own ~14.6% post-close (voting capped at 4.9%) and designate two board members to Victory's 11-member board.

On August 20, 2026, Atlantic American Corporation (AAME) received a notice from Nasdaq stating the company is non-compliant with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for Q2 2026, Form 10-K for year-end 2025, and Form 10-Q for Q1 2026. Nasdaq granted a compliance extension until October 12, 2026, with an interim September 4, 2026 deadline to submit an updated remediation plan. The company reports it is making progress toward filing the delinquent reports, though no specific filing dates or reasons for delays are disclosed.

Avalanche Treasury Corp (AVAT), a $2.2M-asset company that completed its Nasdaq IPO on June 11, 2026, reported a Q2 2026 net loss of $44.7M ($1.54/share), of which $35.7M (80%) was attributable to AVAX fair-value declines and $15.2M to one-time business-combination costs. The company holds 15.3M AVAX ($100M carrying value at quarter-end) and generated $1.5M in staking revenue in Q2 (net of fees). The Board approved a $10M class A share repurchase program. Core G&A expenses were $3.5M.

Tenon Medical has issued Original Issue Discount Senior Convertible Promissory Notes dated March 11, 2026, maturing September 2026 (or December 2026 if extended). The notes feature a 20% OID discount, convert at 80% of 3-day VWAP (floor $0.1567/share), carry a 10% default interest rate, and require mandatory prepayment from financing proceeds at 15% of net proceeds. Specific principal amounts and holder identities are not disclosed in this exhibit form; actual terms appear in the underlying Securities Purchase Agreement dated March 2026.

10% owner MetLife Investment Management, LLC (CCD) bought 880K shares (~$22.0M) on the open market (87% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner MetLife Investment Management, LLC (CHW) bought 440K shares (~$11.0M) on the open market (89% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner CASCADE INVESTMENT, L.L.C. (RSG) bought 571K shares (~$127.0M) on the open market (0.5% of holdings). Open-market insider purchase — historically a bullish signal.

Biomerica Inc. (market cap ~$6.4M) agreed to sell approximately $1.5M of common stock at $1.60 per share to unnamed purchasers in a private placement dated August 20, 2026, closing by August 26, 2026. B. Riley Principal Capital is identified as a purchaser group with board designation rights. The company granted registration rights and imposed 180-day lock-ups on insiders.

On August 24, 2026, Autonomix Medical agreed with an investor to exercise 857,462 warrants (Series D-1 and D-2, issued July 15, 2026) at $5.75/share, generating ~$4.9M gross proceeds. In exchange, the company issued two new unregistered warrant series (E-1 and E-2): 535,913 shares each, exercisable at $6.25/share, 5-year term. New warrants represent 62.5% of exercised shares. Company committed to file resale registration statement within 15 days, maintain trading market listing, and restrict equity issuances through Jan 11, 2027 (no variable-rate transactions). Closing expected ~August 26, 2026. Maxim Group LLC acted as financial advisor.

Flash Sports Media Holdings (market cap ~$3.1M) appealed its Nasdaq suspension to a Hearings Panel on August 26, 2026, following an administrative sequencing error in the listing process. The company reduced approximately $2.0M in debt over two trading days and reports acquisition counterparties remain engaged despite the OTC transfer. No specifics on acquisition targets, timeline, or financial conditions are disclosed.

Healthy Choice Wellness Corp. (market cap ~$11.4M) entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald Co. on August 26, 2026, authorizing sales of up to $2.625 million of Class A common stock at-the-market. Under the agreement, Healthy Choice may issue shares in multiple tranches at market prices subject to agent approval; Cantor receives up to 3.0% commission on gross proceeds. The offering is registered under Form S-3 (File No. 333-291258) and subject to conditions including Host Digital consent (per Section 6(kk) Merger Agreement), suspension rights, and customary SEC/exchange compliance requirements.

SK Biopharmaceuticals Co., Ltd. (SKBP) and Biohaven Bioscience Ireland Limited entered into an exclusive license agreement dated August 26, 2026, for worldwide rights to develop, manufacture, and commercialize Kv7 activators, including BHV-7000 (opakalim), in all indications. SKBP will pay Biohaven $400M upfront ($350M at closing, $50M at 1-year), up to $150M in regulatory milestones, tiered royalties on net sales (reduced for generics/price controls), and assume Knopp Biosciences obligations (~$245M in milestones plus running royalties). Closing is subject to antitrust clearance and other conditions.

Target Hospitality announced a new multi-year contract with a top-five hyperscaler to provide modular accommodations and hospitality services for a data center project in West Texas, expected to generate approximately $250 million in revenue through August 2030 and support ~1,100 individuals. The company will modify existing under-utilized assets requiring less than $15 million capital investment, enabling third-quarter 2026 occupancy. Target raised full-year 2026 guidance: revenue to $435–445M (6% midpoint increase) and Adjusted EBITDA to $105–115M (22% midpoint increase), and projects annualized revenue exceeding $750M and Adjusted EBITDA above $300M exiting 2027.

On 08/18/2026, Senmiao Technology Limited filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State (Filing #20265976248), effective 08/25/2026. Officer Ronggang Zhang authorized the amendment. Prior to this, on 08/04/2026, Senmiao reserved the name 'Valor Energy Inc.' for 90 days (expiring 11/02/2026, Filing #20265946380). The specific substantive amendments to articles are not detailed in the filing; the checkbox marked indicates 'The authorized shares have been amended,' but no share counts, dollar amounts, or detailed terms are disclosed.

Dycom reported Q2 FY2027 record contract revenues of $2.006B (45.6% YoY growth, 16.7% organic), with adjusted EBITDA of $315.5M (15.7% margin) and adjusted diluted EPS of $5.29. The company completed its acquisition of National Technology Integrators (~$22.9M Q2 revenue contribution) and raised full-year FY2027 revenue guidance to $7.48–$7.66B (from prior guidance). Total backlog reached a record $12.242B (+53.2% YoY), with $6.472B in next-12-months backlog. Communications segment revenues of $1.608B grew 16.7% organically; Building Systems (now reported separately post-NTI acquisition) contributed $397.5M with 24.5% adjusted EBITDA margin.

Enhanced Ltd raised ~$29.7M of a targeted $40M via SAFEs (Simple Agreements for Future Equity) in late 2025, immediately preceding its November 2025 business combination agreement with SPAC A Paradise Acquisition Corp (NASDAQ: APAD), consummated May 7, 2026. The company reported net loss of $26.7M in 2025 vs. $4.7M in 2024; accumulated deficit reached $32.0M. Auditors issued going-concern warning citing recurring losses and insufficient cash for operations. No revenue to date; focus is organizing the Enhanced Games sporting event.

Borealis Foods reported preliminary K-12 foodservice revenue increased 110% for the six months ended June 30, 2026 versus June 30, 2025. The company expanded to over 20,000 schools across approximately 2,500 school districts, with products shipped through 106 distributors across 40 states. Revenue figures are unaudited preliminary results subject to adjustment upon completion of Q2 2026 financial statements.

Celcuity submitted a supplemental New Drug Application (sNDA) to the FDA on August 26, 2026, for REVTORPYK (gedatolisib) to treat HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA mutations. The application is supported by Phase 3 VIKTORIA-1 trial data from 350 PIK3CA-mutant subjects, showing REVTORPYK-triplet reduced disease progression/death risk by 50% (HR=0.50; median PFS 11.1 months vs. 5.6 months) and REVTORPYK-doublet by 49% (HR=0.51; median PFS 11.3 months) versus alpelisib plus fulvestrant. REVTORPYK was previously approved July 14, 2026, for PIK3CA wild-type patients; this sNDA expands addressable market to ~40% of HR+/HER2- patients with PIK3CA mutations.

On August 24, 2026, Abundia Global Impact Group's Board authorized a $5 million stock buyback program to repurchase up to approximately 12% of outstanding float at prevailing market prices. The program, which may be executed in open market or private transactions, reflects management's belief the stock is undervalued and complements recent debt restructuring; repurchases are discretionary and may be suspended or terminated at any time.

In July 2026, Worksport achieved record monthly product orders of $2.52M, net sales of $2.22M (up 6.7% from June, 60.6% from March), gross margin of 30.8% (third consecutive month >30%), and calculated a $30M annualized revenue rate. The company reports seven consecutive months of sales growth averaging 12.9% month-over-month, with $0.3M in backlog. All figures are preliminary and unaudited.

Great Elm (market cap ~$30.3M) raised $2.86M from Kennedy Lewis entities (1,353,885 shares @ $2.11/share, July 31, 2025) and $9M from Woodstead Value Fund (4M shares @ $2.25/share plus 2M warrants, August 27, 2025). Kennedy Lewis receives one board director if it maintains 50% ownership and 15% profit interest in real estate venture. Woodstead gets one board seat if it holds ≥2M shares. Both deals include registration rights and director appointment rights. Total new shares issued: ~5.35M shares (~19.4% dilution to the ~27.6M outstanding as of July 31).

Everpure reported Q2 FY2027 revenue of $1.2B (up 38% YoY), with product revenue growing 54% YoY to $687M. The company raised full-year FY2027 revenue guidance from $4.41–$4.51B to $5.03–$5.07B and non-GAAP operating income from $820–$860M to $940–$960M, reflecting confidence in continued momentum. Key wins include a second top-five hyperscaler design win and expansion of AI/Data Intelligence products; however, operating cash flow was negative $136M and free cash flow was negative $238M in Q2.

Adeptus Partners, LLC consented to reference in the S-1/A filing and use of their audit report dated April 15, 2026 (updated July 21, 2026 for Note 14) covering fiscal years 2025 and 2024. The auditor's report contains an explanatory paragraph regarding Starfighters Space's ability to continue as a going concern, a standard disclosure of substantial doubt about the company's viability.

Great Elm Group (market cap ~$30.3M) reported fiscal 2026 net loss of $35.4M (vs. $12.9M prior-year income), driven by $22.2M in unrealized losses on GECC holdings. Despite the loss, the company raised ~$393M across credit and real estate platforms, grew fee-paying AUM to $590M (+7%), and maintained $53.5M cash. GEG repurchased 8.1M shares ($2.00/share avg, $16.1M total) with $23.9M remaining authorization.

Veea Inc. completed a 1-for-20 reverse stock split effective August 28, 2026, combining every 20 shares into 1 share. Concurrently, the company issued three demand promissory notes to NLabs Inc.: two notes of $450,000 each and one of $250,000 (total $1,150,000), all bearing 10% annual interest, due on demand or by December 31, 2026. The reverse split was approved by stockholders on December 30, 2025 and by the board on August 10, 2026.

Splash Beverage Group (not Endovia; this is the actual company in the filing) hired Brady Cobb as Interim CEO at $300,000/year base salary effective June 8, 2026, and Michael Bondurant as Interim COO at $275,000/year base salary, same effective date. Both receive stock options (Cobb: 231,250 shares; Bondurant: 200,000 shares post-reverse-split) and market-cap-based cash bonuses up to $400,000 each in 2026 ($50K at $5M market-cap increase, $50K at $10M increase, then 3% above that capped at $300K). Bonuses accelerate upon Material Transaction. Both are at-will employees; employment commenced retroactively June 8, 2026, agreements signed August 20, 2026.

Gulf Resources entered into a Strategic Cooperation Agreement with Brazilian mining company Montes Verdes Participacoes Ltda. on August 20, 2026, to form a joint venture combining their resources and technology. Montes Verdes guarantees 2027 consolidated sales revenue of at least $180 million and minimum 20% annual sales growth for five years; additional Gulf shares may be issued if targets are met. The agreement aims to expand Gulf's international presence in bromine, lithium, and other minerals amid rising commodity prices.

Future FinTech's Board approved a 1-for-4 reverse stock split without shareholder approval. Outstanding shares reduce from ~32.3M to ~8.1M; authorized common stock reduces from 37.5M to 9.375M shares. Trading resumes on NASDAQ under symbol FTFT with new CUSIP 36117V600 on August 31, 2026. Each shareholder's ownership percentage remains unchanged; fractional shares round up to one whole share.

On August 14–17, 2026, Dare Bioscience completed a registered direct offering and concurrent private placement: issued 4,085,687 common shares and 293,894 pre-funded warrants at $1.37 per share (net proceeds ~$5.3M); issued Series A warrants (4,379,581 shares) and Series B warrants (4,379,581 shares) at $1.37 exercise price; issued placement agent warrants (175,183 shares) at $2.1235 exercise price. This S-1 registers resale of up to 8,934,345 shares issuable upon warrant exercise. Company is tiny ($21.3M market cap), facing Nasdaq delisting risk, and relies on warrant exercise cash to fund operations.

Standard Nuclear completed its July 17, 2026 IPO on NYSE (ticker: STDN), issuing 10.0 million shares at $15/share for $137.7M net proceeds. Contract backlog surged from $91.3M (March 31) to $576.9M (August 26), with Funded Backlog jumping from $8.2M to $119.3M following an August deal with Antares Nuclear (1 MTU firm + 7 MTU option). Q2 2026 revenue was $4.7M (vs. $0.6M in Q2 2025); company delivered first commercial TRISO fuel core and achieved gross profit ($3.2M) for the first time.

10% owner MetLife Investment Management, LLC (CHY) bought 290K shares (~$7.3M) on the open market (87% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner MetLife Investment Management, LLC (CHI) bought 345K shares (~$8.6M) on the open market (88% of holdings). Open-market insider purchase — historically a bullish signal.

Director RAYMOND JOHN T (NGL) bought 300K shares (~$5.1M) on the open market (44% of holdings). Open-market insider purchase — historically a bullish signal.

Executive Chairman RADY ERNEST S (AAT) bought 80K shares (~$1.8M) on the open market (0.9% of holdings). Open-market insider purchase — historically a bullish signal.

CHAIRMAN & CEO Williams Charles Alan (NPB) bought 78K shares (~$1.3M) on the open market (3.2% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Wilks Dan H. (ACDC) bought 607K shares (~$2.9M) on the open market (0.7% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner THRC Holdings, LP (ACDC) bought 607K shares (~$2.9M) on the open market (0.7% of holdings). Open-market insider purchase — historically a bullish signal.

As of August 25, 2026, Capstone Holding Corp. has retired approximately $5.1M of its original $6.82M convertible note principal (75%), leaving $1.72M outstanding across two notes maturing August 29 and October 22, 2026. On August 10, 2026, the company and holder 3i LP agreed to reduce the conversion price from $0.57–$1.10 to $0.2949 per share to enable continued retirement before maturity. Current share count is approximately 21.75 million; if the remaining $1.72M converted at $0.2949, it would represent 6.18M additional shares (28% dilution). The company reports Q2 2026 revenue of $21.5M (+67% YoY), gross profit of $6.0M (+92% YoY), positive Stone Business Adjusted EBITDA of $2.0M, and expects to fund corporate needs through operating cash flow and an equity line facility.

Unifi Manufacturing, Inc. agreed to sell two industrial properties in Yadkin County, North Carolina to Canadian data center operator Enovum Data Centers Corp. for $60,000,000. The sale includes Property X (61.4 acres, 400,000 sq ft building) and a portion of Property Y Complex (62.7 acres, 111,589 sq ft of building space). Earnest money deposit is $2,250,000 ($1,000,000 becomes non-refundable if inspection period extended). Closing expected ~45 days after September 15, 2026 inspection period end. Post-closing, Unifi retains short-term occupancy rights and will leaseback ~[redacted] sq ft of Property X for 5 years. Deal includes earnout provisions: up to $8M per site if 69MW additional power capacity secured within 2 years; declining payments for later achievement. Unifi retains ~[redacted] MW of power capacity for operations.

Akeso (Summit's partner) announced positive Phase III HARMONi-GI1 results in China showing ivonescimab plus chemotherapy achieved statistically significant overall survival superiority versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer, also meeting key secondary endpoints (PFS, ORR). This marks the first Phase III ivonescimab readout outside NSCLC and the first known Phase III study demonstrating OS superiority over anti-PD-(L)1 plus chemotherapy in advanced BTC. Ivonescimab remains investigational in Summit's license territories (US, Europe); drug is approved and commercialized in China for NSCLC.

Somnigroup completed its acquisition of Leggett & Platt on August 26, 2026, in an all-stock transaction valued at $2.3 billion inclusive of L&P's debt. L&P shareholders received 0.1455 Somnigroup shares per L&P share, resulting in ~9% ownership of the combined company on a fully diluted basis. The deal reduces net leverage by 0.2x to ~2.8x EBITDA, identifies $75M in annual run-rate synergies (up from $50M), adds 170 manufacturing facilities across 37 countries and 36,000 employees, and deepens Somnigroup's vertical integration and component-engineering capabilities.

Leonard M. Tannenbaum purchased 163,670 shares of Advanced Flower Capital common stock across six transactions from August 14–25, 2026, at prices ranging $3.01–$3.50 per share, spending approximately $530,000 from personal funds. This accumulation represents a material 4.9% stake relative to the company's $80.9M market cap (~26.5M shares outstanding implied). The filing is a Schedule 13D/A amendment disclosing insider purchases concentrated over a two-week period.